Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/061204external-prioritypatent/WO2010023309A2/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of CU20110043A7publicationCriticalpatent/CU20110043A7/en
Publication of CU23997B1publicationCriticalpatent/CU23997B1/en
Se proporcionan nuevos compuestos, composiciones y métodos de inhibición de la integración de la actividad del provirus de la cinasa Maloney (Cinasa PIM) asociada con tumorigénesis en un sujeto humano o animal. En ciertas modalidades, los compuestos y composiciones son efectivos para inhibir la actividad de cuando menos una cinasa PIM. Los nuevos compuestos y composiciones se pueden utilizar ya sea solos o bien en combinación con cuando menos un agente adicional para el tratamiento de un trastorno mediado por una cinasa de serina/treonina o por un receptor de cinasa de tirosina, tal como cáncer.New compounds, compositions and methods of inhibiting the integration of Maloney kinase provirus activity (PIM kinase) associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective in inhibiting the activity of at least one PIM kinase. The new compounds and compositions can be used either alone or in combination with at least one additional agent for the treatment of a serine / threonine kinase mediated disorder or a tyrosine kinase receptor, such as cancer.
CU2011000043A2009-07-152011-02-28
PICOLINAMIDE DERIVATIVES AS CINASA INHIBITORS
CU23997B1
(en)
Compounds derived from substituted carboxyamide heterocycles, ar antagonist; pharmaceutical composition comprising them; and use in the treatment of prostate cancer.
Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.
Compounds derived from benzimidazole substituted with a substituted pyrazole group, kinase inhibitor fgfr; pharmaceutical composition comprising them; and its use in the treatment of cancer.
HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
Compounds derived from pyridine fused with another heterocycle, smo inhibitors; pharmaceutical composition; and use for the prophylaxis or treatment of cancer.